(ADDV-A) ADDvise - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0001306119
ADDV-A: Lab Equipment, Medical Devices, Pharmaceuticals, Software, Cleanrooms
ADDvise Group AB (publ) is a leading supplier of specialized equipment and solutions to healthcare and research sectors globally, operating across Europe, North America, South America, Asia, and other international markets. The companys operations are divided into two core business units: Lab and Healthcare.
The Lab business unit specializes in providing advanced laboratory infrastructure and equipment, including laboratory furnishings, ventilation systems, climate-controlled environments, and cleanrooms. These solutions are tailored for pharmaceutical companies, biotechnology firms, and research institutions, supporting their operational and scientific needs.
The Healthcare business unit focuses on medical equipment, pharmaceuticals, and consumables, catering to specialties such as urology, gynecology, emergency care, and surgery. The unit also manufactures surgical tables and offers a range of cables, connectors, and wires. Additionally, it provides customized solutions for the rental and sale of medical and laboratory equipment for clinical studies.
Further, the company designs and delivers customized cleanrooms, climate-controlled rooms, and laboratory furniture. It distributes medical devices, including continuous glucose monitors and insulin pumps, as well as orthopedic solutions like implants and surgical instruments. The company also develops software and instruments for quantifying patient mobility, pain levels, and muscle strength.
Other offerings include healthcare and industrial ultrasound devices for medical and non-destructive testing (NDT) applications. The company operates a mail-order pharmacy and develops, manufactures, and markets over-the-counter (OTC) generic drugs for pain management, respiratory conditions, and urological treatments. It also provides products and software for monitoring vital signs in long-term care settings and markets colorimetric CO2 indicators used in respiratory and emergency care.
Originally founded as ADDvise Lab Solutions AB (publ) in 1989, the company rebranded to ADDvise Group AB (publ) to reflect its expanded scope. Headquartered in Stockholm, Sweden, it has established itself as a diversified provider of critical solutions for healthcare and life sciences industries.
Additional Sources for ADDV-A Stock
ADDV-A Stock Overview
Market Cap in USD | 48m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception |
ADDV-A Stock Ratings
Growth 5y | 49.6% |
Fundamental | 46.8% |
Dividend | 1.0% |
Rel. Strength Industry | -39.2 |
Analysts | - |
Fair Price Momentum | 7.91 SEK |
Fair Price DCF | 19.65 SEK |
ADDV-A Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | -100.00% |
Payout Consistency | 1.0% |
ADDV-A Growth Ratios
Growth Correlation 3m | -50.4% |
Growth Correlation 12m | -65.7% |
Growth Correlation 5y | 78.8% |
CAGR 5y | 50.27% |
CAGR/Max DD 5y | 0.63 |
Sharpe Ratio 12m | -0.07 |
Alpha | -43.79 |
Beta | -0.23 |
Volatility | 182.82% |
Current Volume | 2.3k |
Average Volume 20d | 2.5k |
As of March 13, 2025, the stock is trading at SEK 7.84 with a total of 2,301 shares traded.
Over the past week, the price has changed by -14.22%, over one month by +32.88%, over three months by -27.41% and over the past year by -39.22%.
Partly, yes. Based on ValueRay Fundamental Analyses, ADDvise (ST:ADDV-A) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 46.83 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADDV-A as of March 2025 is 7.91. This means that ADDV-A is currently overvalued and has a potential downside of 0.89%.
ADDvise has no consensus analysts rating.
According to ValueRays Forecast Model, ADDV-A ADDvise will be worth about 9.2 in March 2026. The stock is currently trading at 7.84. This means that the stock has a potential upside of +16.96%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 13 | 65.8% |
Analysts Target Price | - | - |
ValueRay Target Price | 9.2 | 17% |